Press Releases

eNUVIO is Launching the OMEGA-96 Device

Today, eNUVIO has announced the launch of their latest innovative microfluidic device for neuronal compartmentalization and co-culture experiments — the OMEGA-96. This first of its kind microplate will help to improve the success and efficiency of drug discovery and safety toxicology in neurological research areas, particularly in the field of neurodegenerative and neuromuscular diseases.

Alfa Chemistry Provides Wide Choices of Pyridinium Ionic Liquids for Scientific Research

Pyridinium ionic liquids are widely applied in Diels-Alder reaction, Friedel-Crafts reaction, Suzuki reaction, Grignard Reaction as well as the synthesis of some pharmaceutical agents. To meet the growing needs for this type of chemicals, Alfa Chemistry recently announced to provide wide choices of pyridinium ionic liquids for clients both at home and abroad. Most of them are in stock and can be delivered to buyers within a few business days.

Shimmer’s Verisense® Wearable Sensing Platform Selected for Boston University Brain Health Studies

These studies, which are funded by the American Heart Association, will use wearable sensors to increase knowledge of the links between brain and heart health.

‘UK government can deliver Brexit benefit with world’s best medicines security’ say FarmaTrust

Company forewarns the UK is risking fake COVID-19 vaccines and other medicines without a new system

Alfa Chemistry: Instrumental Analytical Reagents Are Now Accessible

Alfa Chemistry announced in a statement that the company starts to provide varieties of instrumental analytical reagents for consumers worldwide. In addition to other reagents that are previously released, now the company’s supply range of products are widely broadened, which encompasses: chromatography standards and derivatization reagents, Ion Sensor Materials, Laboratory Supplies, LPLC/TLC/Paper Chromatography, and Titration.

Ubiquigent and the University of York Awarded a Grant to Explore the Potential of Deubiquitylase (DUB) Enzyme Inhibitors to Address Neglected Tropical Diseases

Ubiquigent today announced a collaboration with Mottram Laboratory at the University of York to investigate the inhibition of deubiquitylase (DUB) enzymes expressed by the protozoan Leishmania mexicana for the treatment of leishmaniasis.

The biotech company baseclick GmbH launched a new and highly efficient method for SARS-CoV-2 mutation analysis

https://news.lifesciencenewswire.com/newsroom/the-biotech-company-baseclick-gmbh-launched-a-new-and-highly-efficient-method-for-sars-cov-2-mutation-analysis

Thermo Fisher Scientific Releases SARS-CoV-2 Optimized Precipitation Reagent* and Enrichment Kits* for Isolating Virus Particles

Thermo Fisher just introduced the new Invitrogen Intact Virus Precipitation Reagent and Dynabeads Intact Virus Enrichment Kits, which are optimized to isolate intact SARS-CoV-2 virus particles to support viral research.

MedAI: Explore Therapeutic Antibody Discovery and Development for Disease Treatment

Bio-drugs are more extensively used in disease treatment, especially in the past decade. MedAI, an expert of AI-assisted R&D research company, announces that it now provides AI-driven solutions for the development of therapeutic antibodies, which could be used for the treatment of pathologies such as oncology.

EXTENSIVE LINE OF LIQUID STABLE & READY-TO-USE CLINICAL REFERENCE MATERIALS AVAILABLE FROM VERICHEM LABORATORIES

VERICHEM LABORATORIES has announced availability of an extensive line of ready-to-use, liquid stable Clinical Reference Materials intended for the calibration and calibration verification of clinical testing systems.

LabPON Adopts Proscia’s Concentriq to Meet Demand for Diagnostic Services Amid Rising Cancer Burden

Transition to open, scalable, and intuitive platform empowers leading laboratory to realize full potential of AI-enabled digital pathology

BOC Sciences’s CDMO Helps Overcome the Last Hurdle of ADC R&D

Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its sites in Preston, North Manchester and North London

Panthera’s clinical trial sites are helping to evaluate an alternative AstraZeneca vaccine for people who are unable to have the currently approved Covid-19 vaccines. The treatment is aimed at helping those people with a compromised immune system, who cannot be vaccinated, vaccine hesitant and those who are unlikely to respond to a vaccination.

Biotech Team Develops ELISA Protocol for COVID-19 IgG Antibody Detection

ZTA Biotech, a Budapest-based biotech startup, has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol. This new detection method can help determine whether patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients. Initial equipment and personnel costs are low and are proportional to the desired monthly production. The test can also be adapted to potential virus mutations, based on sequencing data.

Sera Prognostics Partners With Anthem and HealthCore to Improve Outcomes for Preterm Babies

BOC RNA and Dr. Shiyue Fang Announced Plans to Cooperate Closely in Sensitive DNA/RNA Synthesis

Data Analysis at AI & Medicine: PrediXcan Based Analysis and BSLMM Prediction

Matexcel Provides a Wide Selection of Antimicrobial Material Products

AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease

AMZELL to initiate a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.

IntegrateRNA Launches tRNA Services for RNA Discovery and Many Common Diseases Treatment